Advertisement
Advertisement
U.S. Markets close in 4 hrs 1 min
Advertisement
Advertisement
Advertisement
Advertisement

UroGen Pharma Ltd. (URGN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.97+0.07 (+0.94%)
As of 10:53AM EDT. Market open.
Advertisement

UroGen Pharma Ltd.

400 Alexander Park
Princeton, NJ 08540
United States
646 768 9780
https://www.urogen.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees192

Key Executives

NameTitlePayExercisedYear Born
Ms. Elizabeth A. BarrettPres, CEO & Director1.25MN/A1962
Mr. Jason Drew SmithGen. Counsel, Chief Compliance Officer & Corp. Sec.616.34kN/A1972
Dr. Mark P. Schoenberg M.D.Chief Medical Officer579.5kN/A1958
Mr. Dong KimChief Financial OfficerN/AN/A1977
Vincent I. PerroneSr. Director of Investor RelationsN/AN/AN/A
Eric Van ZantenSr. Director of CommunicationsN/AN/AN/A
Dr. Sari Prutchi-Sagiv Ph.D.Marketing DirectorN/AN/AN/A
Dr. Marina KonortyExec. VP of R&D and Technical OperationsN/AN/AN/A
Mr. Jeffrey Bova M.B.A.Chief Commercial OfficerN/AN/AN/A
Mr. James Ottinger R.ph.Exec. VP of Regulatory Affairs & QualityN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Corporate Governance

UroGen Pharma Ltd.’s ISS Governance QualityScore as of July 31, 2022 is 6. The pillar scores are Audit: 8; Board: 3; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement